Cytek Biosciences (CTKB) Cost of Revenue (2020 - 2026)

Cytek Biosciences (CTKB) has reported Cost of Revenue for 7 consecutive years, with $19.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 8.9% year-over-year to $19.8 million; the trailing twelve-month figure through Jun 2026 stood at $96.7 million (up 8.2% YoY), and the FY2025 full-year result was $97.0 million, up 8.6% from the prior year.
• Cost of Revenue retreated to $19.8 million in Q2 2026 per CTKB's latest filing, from $22.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $29.3 million in Q4 2025 and bottomed at $13.6 million in Q3 2022.
• Historically, Cost of Revenue has averaged $20.9 million across 5 years, with a median of $21.4 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Cost of Revenue jumped 52.93% in 2023, then slipped 8.9% in 2026.
• Over 5 years, Cost of Revenue stood at $19.0 million in 2022, then soared by 32.82% to $25.2 million in 2023, then decreased by 5.4% to $23.8 million in 2024, then gained by 22.8% to $29.3 million in 2025, then sank by 32.32% to $19.8 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $19.8 million, $22.9 million, and $29.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.